Found: 98
Select item for more details and to access through your institution.
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 7, p. 1639, doi. 10.1007/s13300-024-01590-x
- By:
- Publication type:
- Article
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 5, p. 1099, doi. 10.1007/s13300-024-01550-5
- By:
- Publication type:
- Article
Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 4, p. 869, doi. 10.1007/s13300-024-01551-4
- By:
- Publication type:
- Article
MEJORA DE LA A1C Y DEL TIEMPO EN RANGO (TER) CON LA INSULINA SEMANAL ICODEC CONTRA LA INSULINA GLAGINA U100 EN PACIENTES CON DIABETES TIPO 2 SIN USO PREVIO DE INSULINA - ONWARDS-1.
- Published in:
- Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2023, v. 10, p. 21
- By:
- Publication type:
- Article
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01949-7
- By:
- Publication type:
- Article
Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2243, doi. 10.1111/dom.15102
- By:
- Publication type:
- Article
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 6, p. 895, doi. 10.1007/s10198-022-01514-1
- By:
- Publication type:
- Article
Diabetic retinopathy.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 3, p. 73
- By:
- Publication type:
- Article
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 639, doi. 10.1111/dom.14917
- By:
- Publication type:
- Article
Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 878, doi. 10.1111/dom.14938
- By:
- Publication type:
- Article
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond.
- Published in:
- Endocrinology & Metabolism, 2023, v. 38, n. 1, p. 25, doi. 10.3803/EnM.2022.1642
- By:
- Publication type:
- Article
Fat – pharmacological therapies.
- Published in:
- British Journal of Diabetes, 2022, v. 22, p. S59, doi. 10.15277/bjd.2022.367
- By:
- Publication type:
- Article
The place of glucagon-like 1 peptide receptor agonists (GLP-1RAs) in the new NICE guidelines - what is going on?
- Published in:
- British Journal of Diabetes, 2022, v. 22, n. 2, p. 69, doi. 10.15277/bjd.2022.381
- By:
- Publication type:
- Article
The endocrine pancreas during exercise in people with and without type 1 diabetes: Beyond the beta-cell.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.981723
- By:
- Publication type:
- Article
Ageing well with diabetes: A workshop to co‐design research recommendations for improving the diabetes care of older people.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 7, p. 1, doi. 10.1111/dme.14795
- By:
- Publication type:
- Article
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 5, p. 889, doi. 10.1007/s13300-022-01242-y
- By:
- Publication type:
- Article
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14769
- By:
- Publication type:
- Article
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort study.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 3, p. 1, doi. 10.1111/dme.14697
- By:
- Publication type:
- Article
New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 97, doi. 10.1007/s40265-021-01655-2
- By:
- Publication type:
- Article
Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 2, p. 225, doi. 10.1007/s13300-021-01201-z
- By:
- Publication type:
- Article
A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 1, p. 33, doi. 10.1007/s12325-021-01927-z
- By:
- Publication type:
- Article
Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.
- Published in:
- touchREVIEWS in Endocrinology, 2022, v. 18, n. 1, p. 43, doi. 10.17925/ee.2022.18.1.43
- By:
- Publication type:
- Article
Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, p. 30, doi. 10.1111/dom.14487
- By:
- Publication type:
- Article
Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, p. 30, doi. 10.1111/dom.14487
- By:
- Publication type:
- Article
Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 9, p. 2267, doi. 10.1007/s13300-021-01116-9
- By:
- Publication type:
- Article
A woman with poorly controlled type 1 diabetes and pruritic papules on her buttocks.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.
- Published in:
- Drugs, 2021, v. 81, n. 11, p. 1243, doi. 10.1007/s40265-021-01538-6
- By:
- Publication type:
- Article
664-P: Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-664-P
- By:
- Publication type:
- Article
660-P: Greater Proportions of Subjects Achieved Composite Endpoints with Once-Weekly Semaglutide vs. Comparators in SUSTAIN Trials.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-660-P
- By:
- Publication type:
- Article
One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 6, p. 1593, doi. 10.1007/s13300-021-01061-7
- By:
- Publication type:
- Article
Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation.
- Published in:
- Diabetic Medicine, 2021, v. 38, n. 6, p. 1, doi. 10.1111/dme.14523
- By:
- Publication type:
- Article
Costs of the COVID‐19 pandemic associated with obesity in Europe: A health‐care cost model.
- Published in:
- Clinical Obesity, 2021, v. 11, n. 2, p. 1, doi. 10.1111/cob.12442
- By:
- Publication type:
- Article
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 3, p. 801, doi. 10.1007/s13300-021-01015-z
- By:
- Publication type:
- Article
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 143, doi. 10.1007/s13300-020-00981-0
- By:
- Publication type:
- Article
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2487, doi. 10.1111/dom.14160
- By:
- Publication type:
- Article
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2077, doi. 10.1111/dom.14126
- By:
- Publication type:
- Article
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2193, doi. 10.1111/dom.14140
- By:
- Publication type:
- Article
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
- Published in:
- Cardiovascular Diabetology, 2020, v. 19, n. 1, p. N.PAG, doi. 10.1186/s12933-020-01106-4
- By:
- Publication type:
- Article
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1690, doi. 10.1111/dom.14079
- By:
- Publication type:
- Article
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-278-OR
- By:
- Publication type:
- Article
Cover Image, Volume 22, Issue 3.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 1, doi. 10.1111/dom.14000
- By:
- Publication type:
- Article
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896
- By:
- Publication type:
- Article
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 442, doi. 10.1111/dom.13955
- By:
- Publication type:
- Article
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2020, v. 13, p. 433, doi. 10.2147/DMSO.S193693
- By:
- Publication type:
- Article
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 259, doi. 10.1007/s13300-019-00736-6
- By:
- Publication type:
- Article
Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2450, doi. 10.1111/dom.13826
- By:
- Publication type:
- Article
Performance of the Freestyle Libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: A secondary outcome analysis of a randomized crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2505, doi. 10.1111/dom.13835
- By:
- Publication type:
- Article
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1745, doi. 10.1111/dom.13698
- By:
- Publication type:
- Article